Skip to main content

Table 1 Norovirus travel study: data collection event summary

From: Estimating the incidence of norovirus acute gastroenteritis among US and European international travelers to areas of moderate to high risk of traveler’s diarrhea: a prospective cohort study protocol

Content

Data Collection Event

Pre-Travel

Peri-Travel

Post-Travel

Recruitment

Baseline

Clinical Samplea

Daily Diary

Diary

Day 2

Diary

Day 7

Diary

Day 14

Clinical Sampleb,c

3 Month Follow-Upc

6 Month Follow-Upc

Eligibility

         

Demographics

         

Travel

 Plans/Itinerary

 

     

 Type/Reason for Travel

 

        

 Behavior/Activities

   

     

 Past 3 Months

 

      

Health Information

 Blood Type

 

        

 Pre-Existing Condition

 

        

 Regular Bowel Patterns

 

      

 Non-Specific Symptoms

 

 

 

 Illness in Week Prior to Travel*

   

      

Medication/Vaccination

 Medications

 

 

 

 Vaccinations

 

 

   

Acute Gastroenteritis

 

 

 

 Week Prior to Travel*

   

      

 Medical Care

   

 

 Direct and Indirect Costs

     

 

 Impact on Daily Function

   

  

 Impact on Travel Plans / Planned Activities

   

    

Travel Companion and Household Illness

      

   

New Onset Conditions / Potential Post-Infectious Sequelae

        

 Medical Care

        

 Direct and Indirect Costs

        

 Impact on Daily Function

        

Self-Collected Stool

  

    

  
  1. aPre-travel clinical sample provided within 7 days of travel start
  2. bPost-travel clinical sample provided within 14 days of symptom onset if traveler experienced acute gastroenteritis between day 2 of travel and day 2 post-travel or within 14 days of travel return if traveler was selected at study enrollment to provide a post-travel stool sample regardless of the absence of acute gastroenteritis symptoms while traveling
  3. cData collection event for a subset of the study participants including those with acute gastroenteritis between day 2 of travel and day 2 post-travel or 25% of study participants selected at enrollment to provide post-travel stool samples and extended 3 and 6-month follow-up